Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
DATA GRAPHICS | Product Development Retatrutide data strengthen Lillys hand in high-BMI obesity Phase III data put weight loss above CagriSemas benchmark, with tolerability that may be good enough to preserve a commercial edge May 21, 2026 7:09 PM UTC Lilly again has the frontrunner in the weight loss Olympics: its triple agonist retatrutide showed greater Phase III obesity efficacy than Novo Nordisks dual-acting CagriSema, with a tolerability profile that does not appear markedly worse
One area of focus is long-term studies that follow patients over several years
It has been available longer and costs less than tirzepatide across both brand-name and compounded options
People with existing kidney problems may experience a worsening of their symptoms if they experience dehydration while taking Zepbound
Looking for a Different Strength
A recent review by Campbell [19] attempts to reconcile the paradoxical observations
